Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Current Molecular Pharmacology|July 17, 2015
Current Immunotherapies for Renal Cell CarcinomaMhd Yaser Al-Marrawi, Sheldon L HolderExpert Opinion on Pharmacotherapy|April 8, 2011
Pazopanib for the treatment of renal cancerMhd Yaser Al-Marrawi, Brian RiniCancer Biology & Therapy|June 25, 2013
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancerMhd Yaser Al-Marrawi, Bikramajit Singh Saroya, Matthew C Brennan, et al.Current Cancer Drug Targets|November 27, 2013
PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistanceSheldon L Holder, Sarki A AbdulkadirOncotarget|December 10, 2017
The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumorsJeffrey Small, Erik Washburn, Karmaine Millington, et al.Cancer Causes & Control : CCC|November 17, 2019
Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancerMing Wang, Guangqing Chi, Yosef Bodovski, et al.Cancer Biology & Therapy|February 19, 2015
Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expressionJacob S Lipkin, Syed M Rizvi, Zoran Gatalica, et al.European Urology Focus|July 30, 2017
Molecular Characterization of Bladder Cancer in Smokers versus NonsmokersMonika Joshi, Sherri Z Millis, David Arguello, et al.Cancer Medicine|October 24, 2020
Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancerMonika Joshi, Petros Grivas, Amir Mortazavi, et al.American Journal of Cancer Research|April 20, 2026
PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axisKimberly S Meza, Kimberly Seymour, Elias Ou Eteshola, et al.Pageof 2